Literature DB >> 30940412

Non-HACEK Gram-negative bacillus endocarditis.

M Ertugrul Mercan1, F Arslan2, S Ozyavuz Alp3, A Atilla4, D Seyman5, G Guliyeva6, B Kayaaslan7, S Sari8, B Mutay Suntur9, B Isik10, A Mert11.   

Abstract

PATIENTS AND METHODS: Retrospective analysis of clinical data using 26 diagnosed non-HACEK Gram-negative infective endocarditis cases from nine hospitals in Turkey.
RESULTS: Mean age of patients was 53 (28-84) years, with a 23% case fatality. Nineteen (73%) of the 26 patients had at least one predisposing factor. The presence of a central venous catheter was the most common predisposing factor (7/26 patients). Pseudomonasaeruginosa (7/26 patients) and Escherichiacoli (7/26 patients) were the most common pathogens. The median duration of the antibiotic therapy was 42 days (range 3-84 days). Surgical procedures were performed in 10 patients. The case fatality was similar in patients who did or did not undergo surgery (20% vs. 25%).
Copyright © 2019. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Bactéries à Gram négatif; Catheterization; Cathétérisme; Endocardite; Endocarditis; Gram-negative bacteria

Mesh:

Year:  2019        PMID: 30940412     DOI: 10.1016/j.medmal.2019.03.013

Source DB:  PubMed          Journal:  Med Mal Infect        ISSN: 0399-077X            Impact factor:   2.152


  3 in total

1.  An Unusual Case of Neisseria flavescens/subflava Group Tricuspid Valve Endocarditis in a Patient With Previously Treated Methicillin-Resistant Staphylococcus aureus Endocarditis.

Authors:  Anup Solsi; Dawood Findakly; Nawfal Mihyawi; Ayman R Fath
Journal:  Cureus       Date:  2020-08-14

Review 2.  Infective endocarditis by Proteus species: a systematic review.

Authors:  Petros Ioannou; Georgios Vougiouklakis
Journal:  Germs       Date:  2020-09-01

3.  Clinical outcomes of combination versus monotherapy for gram negative non-HACEK infective endocarditis.

Authors:  Ashley Lorenz; Mohammad Mahdee E Sobhanie; Libby Orzel; Kelci Coe; Lynn Wardlow
Journal:  Diagn Microbiol Infect Dis       Date:  2021-07-24       Impact factor: 2.803

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.